322 related articles for article (PubMed ID: 29156380)
1. Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
Aksoydan B; Kantarcioglu I; Erol I; Salmas RE; Durdagi S
J Mol Graph Model; 2018 Jan; 79():103-117. PubMed ID: 29156380
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
Aksoydan B; Kantarcioglu I; Erol I; Salmas RE; Durdagi S
J Mol Graph Model; 2017 Oct; 77():240-249. PubMed ID: 28957753
[TBL] [Abstract][Full Text] [Related]
3. Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation.
Durdagi S; Aksoydan B; Erol I; Kantarcioglu I; Ergun Y; Bulut G; Acar M; Avsar T; Liapakis G; Karageorgos V; Salmas RE; Sergi B; Alkhatib S; Turan G; Yigit BN; Cantasir K; Kurt B; Kilic T
Eur J Med Chem; 2018 Feb; 145():273-290. PubMed ID: 29329002
[TBL] [Abstract][Full Text] [Related]
4. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
5. First universal pharmacophore model for hERG1 K
Durdagi S; Erol I; Salmas RE; Patterson M; Noskov SY
J Mol Graph Model; 2017 Jun; 74():153-170. PubMed ID: 28499268
[TBL] [Abstract][Full Text] [Related]
6. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
Kayık G; Tüzün NŞ; Durdagi S
J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling, quantum polarized ligand docking and structure-based 3D-QSAR analysis of the imidazole series as dual AT(1) and ET(A) receptor antagonists.
Singh KD; Muthusamy K
Acta Pharmacol Sin; 2013 Dec; 34(12):1592-606. PubMed ID: 24304920
[TBL] [Abstract][Full Text] [Related]
8. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
[TBL] [Abstract][Full Text] [Related]
10. Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors.
Zhou H; Wang C; Ye J; Chen H; Tao R
Gene; 2017 Dec; 637():63-71. PubMed ID: 28939339
[TBL] [Abstract][Full Text] [Related]
11. Multiple e-pharmacophore modelling pooled with high-throughput virtual screening, docking and molecular dynamics simulations to discover potential inhibitors of Plasmodium falciparum lactate dehydrogenase (PfLDH).
Saxena S; Durgam L; Guruprasad L
J Biomol Struct Dyn; 2019 Apr; 37(7):1783-1799. PubMed ID: 29718775
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
13. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
14. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.
Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J
J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340
[TBL] [Abstract][Full Text] [Related]
15. Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach.
Kesharwani RK; Singh DV; Misra K
J Vector Borne Dis; 2013; 50(2):93-102. PubMed ID: 23995310
[TBL] [Abstract][Full Text] [Related]
16. Revealing Molecular Determinants of hERG Blocker and Activator Binding.
Dickson CJ; Velez-Vega C; Duca JS
J Chem Inf Model; 2020 Jan; 60(1):192-203. PubMed ID: 31880933
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
19. Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands.
John A; Vetrivel U; Subramanian K; Deepa PR
J Biomol Struct Dyn; 2017 May; 35(6):1350-1366. PubMed ID: 27145135
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into the binding mode of flavonols with the active site of matrix metalloproteinase-9 through molecular docking and molecular dynamic simulations studies.
Pradiba D; Aarthy M; Shunmugapriya V; Singh SK; Vasanthi M
J Biomol Struct Dyn; 2018 Nov; 36(14):3718-3739. PubMed ID: 29068268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]